[PP.13.16] EFFECTS OF COMBINATION OF ANGIOTENSIN II RECEPTOR ANTAGONIST WITH CALCIUM ANTAGONIST IN HYPERTENSIVE PATIENTS WITH CORONARY HEART DISEASE AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

    loading  Checking for direct PDF access through Ovid

Abstract

Objective:

To evaluate the effects of valsartan/amlodipine (V/A) fixed combination for standard therapy of arterial hypertension (AH) and coronary heart disease (CHD) in smokers with chronic obstructive pulmonary disease (COPD)

Design and method:

36 smoker male with AH (DBP 90–110 mmHg and/or SBP 140 −180 mmHg), CHD and COPD were randomized into 2 groups (gr): I gr (n = 18, 55,8 ± 5,9 yrs) which received angiotensin-converting enzyme inhibitor and II gr (n = 18, 58,0 ± 4,9 yrs) which treated with the fixed combination V/A (160 mg/5–10 mg). All pts received selective beta-blockers, 16.7% of pts I and II grs - diuretics. The duration of the study was 4 months. The trail includes bicycle exercise stress test (PE); echocardiography; spirometry (forced vital capacity, FVC; forced expiratory volume in 1 second, FEV1); 24-hour ambulatory BP monitoring; questionnaires as SGRQ and Quality of Life SF-36.

Results:

Treatment with V/A significant (p < 0.001) decreased of office SBP (−39.2 ± 9.7 mmHg), DBP (−16.9 ± 5,7 mmHg), pulse BP (−22.2 ± 5.9 mmHg) vs the absence of such dynamics in pts of I gr. Also the average 24 h SBP/DBP was reduced by −10.6/9.3% (p < 0.001), daytime SBP/DBP by −11.6/9.8% (p < 0.01), nighttime SBP/DBP by −9.6/8.4% (p < 0.01). After V/A therapy there was observed increasing of the duration of the PE (22.2%, p < 0.01), threshold power (23.6%, p < 0.01), time before the development of angina pectoris (8.6%, p < 0.05) and myocardial ischemia (8.3%, p < 0.05). In pts of I gr there was a decrease of the duration of the PE (−10.2%, p < 0.05) and time to the development of angina pectoris (−29%, p < 0.05). In II gr we have found positive changes in structural parameters of the heart and decrease of mean pulmonary artery pressure. After V/A therapy there was increase of FVC (by 14.8%, p < 0.05), prebronchodilator FEV1 (by 11.7%, p < 0.05) and FEV1 after administration of salbutamol (by 12.5%, p < 0.05). After V/A therapy there was the improvement of psychological status and quality of life.

Conclusions:

Combination therapy with V/A have complementary mechanisms of action, effectively decreases the levels of office and ambulatory BP, mean pulmonary artery pressure, respiratory symptoms, improves exercise tolerance, and health-related quality of life in smokers with co-morbidities.

Related Topics

    loading  Loading Related Articles